Skip to main content

Table 2 A comparison of the completer and non-completer groups

From: Predictors of long-term cognitive outcome in Alzheimer's disease

  Completers Non-completers P- value
Variable N = 368/44% N = 475/56%  
Female gender 64% 62% 0.614
APOE ε4 carrier 67% 69% 0.652
Estimated age at onset, yearsa 71.8 ± 7.4 72.1 ± 7.5 0.513
Age at first assessment, yearsa 74.9 ± 7.1 75.0 ± 7.2 0.744
Education, yearsa 9.4 ± 2.5 9.4 ± 2.5 0.978
MMSE score at baselinea 22.3 ± 3.4 20.7 ± 3.9 < 0.001
ADAS-cog score (0 to 70) at baselinea 18.2 ± 8.3 22.4 ± 8.9 < 0.001
IADL score at baselinea 14.5 ± 5.3 16.9 ± 5.2 < 0.001
PSMS score at baselinea 7.0 ± 1.7 7.8 ± 2.3 < 0.001
Number of medications at baselinea 2.8 ± 2.5 2.8 ± 2.3 0.827
NSAIDs/Acetylsalicylic acid 29% 31% 0.649
ChEI-doseb 70% 63% < 0.001
  1. a Mean ± standard deviation
  2. bMean percentage of the maximum recommended dose, that is, 10 mg donepezil, 12 mg rivastigmine and 24 mg galantamine.
  3. Abbreviations: ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; APOE, Apolipoprotein E; IADL, Instrumental Activities of Daily Living scale; MMSE, Mini-Mental State Examination; NSAID, Nonsteroidal anti-inflammatory drugs; PSMS, Physical Self-Maintenance Scale.